Oban combines the power of computational structural and chemotype analysis with AI-based “druggability” filters to create a faster, more efficient path to new GPCR-focused medicines.
Oban combines the power of computational structural and chemotype analysis with AI-based “druggability” filters to create a faster, more efficient path to new GPCR-focused medicines.
Technology
GPCR Allosteric Therapeutics
In addition to the orthosteric site where natural signaling molecules (such as neurotransmitters and hormones) act or where direct agonist or antagonist drugs act, GPCRs have allosteric sites – other pockets*, physically separate from the orthosteric site, where different molecules can act to modulate GPCR functioning in response to the natural chemical signal.
* “An t-Òban” (Scottish gaelic) meaning: “The Little Bay”
positive allosteric modulator (PAM) binding to the GPCR’s allosteric site
Pipeline
Advancing
Precision GPCR
Modulation
Oban’s pipeline is diversified with clinically validated targets for metabolic and neuropsychiatric indications where allosteric modulators have the potential to offer substantial efficacy with the advantage of fewer side effects than traditional (orthosteric) GPCR drugs.
